A snipit from The Australian newspaper today..
" biotech Daily sage Mark Sinatra etmates the testosterone replacement market could be worth US 1.4 - 1.6bn by 2012, a year after Axiron's planned launch. Assuming 10% market share and a 20% royalty rate, this equates to $US 28- 32Mil. If Axiron grabs a 50% share, this rises to $US140- $US160mil.
We had Acrux as a long term buy at $2.42 in March. Given the time lag involved in royalties flowing, we suggest myopic investors take profits. Otherwise it's a HOLD.
The full take on this story is on today's Australian paper by Tim Boreham.
DYOR
get ready for blastoff, page-14
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.89M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3903 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.4¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable